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Thyroid cancer as a population problem 
The increase in the prevalence of thyroid cancer, which 
is the most common endocrine carcinoma has been 
observed within the last three decades. It is estimated 
that by 2019 thyroid cancer will have been the third most 
prevalent malignant tumor in women in the USA (1). 
This phenomenon is observed worldwide. For instance, 
the standardized incidence rate in Poland was 4.9 per 
100,000 inhabitants whereas in 1990 it was only 1.0 (2). 
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Abstract: Papillary thyroid cancer (PTC) offers excellent prognosis, however relapse risk or persistent 
disease is related to ~30%. Currently, attention is paid to the possibility of patient group selection of 
different risk of unfavorable outcome to match a particular therapeutic approach. Therefore, interest in 
new prognostic and predictive markers known preoperatively is observed. BRAF V600E mutation is such 
a marker. Many studies analyzing the prevalence of the mutation and its relationship with other clinico-
pathological risk factors were reported but with controversial conclusions. The prognostic significance of 
BRAF mutation was confirmed by some single centre studies, a few meta-analyses and a large multicenter 
retrospective international study. They confirmed a correlation between the mutation and the risk of 
recurrence. The strongest argument against using BRAF mutation as an independent prognostic and 
predictive factor in PTC is its high prevalence (30–80%). At present it seems that BRAF mutation is one of 
the factors influencing the prognosis and it should be analyzed in correlation with other prognostic factors. 
The most recent ATA recommendations do not indicate a routine application of BRAF status for initial risk 
stratification in differentiated thyroid cancer due to a lack of evident confirmation of a direct influence of 
mutation on the increase in relapse risk. However, ATA demonstrates the continuous risk scale for the relapse 
risk assessment, considering BRAF and/or TERT status. At present, researchers are working on determining 
the role of BRAF mutation in patients from a low-risk group and its correlations with others molecular 
events. Currently, BRAF mutation cannot be used as a single, independent predictive factor. However, its 
usefulness in the context of other molecular and clinico-pathological risk factors cannot be excluded. They 
may be used to make modern prognostic scales of relapse risk and be applied to individualized diagnostic and 
therapeutic strategy for PTC patients. 
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The fact whether it is a real increase in incidence or the 
increase in the detection due to the development of more 
precise diagnostic approaches (sensitive ultrasound, access 
to fine needle aspiration biopsy) is of lesser significance. 
As a consequence, the population of newly detected low-
advanced thyroid cancers is constantly growing (3). This has 
one more time resulted in the discussion on optimization 
of therapeutic strategy. The strategy is related to avoid 
overtreatment (with unnecessary exposing patients to an 
increased risk of complications) and undertreatment (i.e., 
increase in the risk of recurrence and treatment failure) (4-7). 
The risk of recurrence in papillary thyroid cancer 
(PTC)
PTC represents the majority of thyroid carcinomas (~80–
90%). It is characterized by excellent prognosis, almost 
100% probability of 5-year overall survival (particularly 
in low-advanced cases). Therefore, in PTC the risk of 
disease recurrence is most frequently analyzed in relation 
to the prognosis, i.e., the disease-free survival but not the 
overall survival unlike in other types of cancers with higher 
mortality rates (8). 
The risk of relapse or persistent disease is related to 
about 30% of PTC patients and depends, among other 
things, on the adopted definition of recurrence (8). 
The incidence of recurrence depends on whether clinical 
detection (structural disease) is considered alone or whether 
it is analyzed together with biochemical recurrence. 
From the perspective of a surgeon, structural recurrence 
seems to be the most significant due to the fact that these 
patients are most frequently scheduled for surgery. In 
the context of the therapeutic strategy, the significance 
of biochemical recurrence cannot be omitted since such 
patients require a change in routine diagnostic and 
therapeutic management, e.g., additional treatment with 
radioactive iodine or increased follow-ups. 
Prognostic scales of risk assessment
Currently, much attention is paid to the possibility of 
patient group selection of different risk of unfavorable 
outcome in order to match a particular therapeutic 
approach (8-11). 
The issue is not new since for many years different 
prognostic scales have been employed on the basis of which 
the risk of relapse and the management are prepared. The 
TNM staging classification, introduced in 1987 by UICC 
and later accepted by AJCC, is the most common system 
of cancer classification, including thyroid carcinomas. 
It allowed to select four stages of clinical advancement, 
depending on the prognosis. In the case of differentiated 
thyroid carcinomas, the above classification additionally 
considers the age factor (12) (Table 1). 
Additionally, some centers individualized their approach 
to the assessment of prognosis for differentiated thyroid 
carcinoma by establishing their own prognostic scales, the 
aim of which is to group patients into adequate risk groups, 
which allows optimization of treatment modality. The 
following are the most commonly employed scales: AGES, 
AMES and MACIS (13-15). All of them consider two major 
prognostic factors, i.e., age at diagnosis and the presence of 
distant metastases. Furthermore, the following are analyzed, 
depending on the scale: tumor size, local advancement, 
extent of surgery and histological grading (Table 2). 
All of the scales and the assessment of other histological 
risk factors (e.g., histological subtype, multifocality, 
angioinvasion, thyroid capsule infiltration) are possible 
after obtaining the results of postoperative histological 
examination. Consequently, they do not offer the possibility 
for planning the extent of surgery and only allow to 
establish the adjuvant treatment, e.g., 131-iodine therapy. 
Therefore, interest in new prognostic and predictive 
markers known preoperatively has been observed recently. 
BRAF V600E mutation is an example of such a marker (16).
 
BRAF mutation—one of the most frequent 
events in the pathogenesis of PTC
The beginning of 2000 marked the interest in BRAF gene 
mutation in thyroid cancer. At that time studies on the 
role of the mutation in other cancers (e.g., melanoma, 
colon cancer) had been already known (15). BRAF gene is 
localized on chromosome 7.
It codes cytoplasmic serine/threonine kinase which 
influences the activation of mitogen-activated pathway 
kinases (MAPK). BRAF gene mutations activate the MAPK 
pathway resulting in the intensity of cellular proliferation, 
inhibition of differentiation and apoptosis. In other words, 
they lead to a loss of control over the cellular cycle, 
initiating the development of malignancy as a result. BRAF 
mutation is one of the most prevalent molecular events in 
the pathogenesis of PTC in adults (16). Point mutation 
T1799A is the most common and the most examined 
mutation of all BRAF gene mutations. It results in the 
exchanging valine to glutamate at residue 600 near the 
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Table 1 Staging system (TNM classification for differentiated cancers) (12)
Stage T feature (tumor) N feature (lymph node metastases) M feature (distant metastases)
Age <45 years of age 
Stage I Each T Each N M0
Stage II Each T Each N M1
Age >45 years of age 
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3; T1–T3 N0; N1a M0; M0
Stage IV
IVa T4a; T1–T3 N0 or N1a; N1b M0; M0
IVb T4b Each N M0
IVc Each T Each N M1
T1, tumor of up to 2 cm in diameter (largest dimension), limited to the thyroid; T2, tumor of 2–4 cm diameter (largest dimension), limited to 
the thyroid; T3, tumor >4 cm (largest dimension), limited to the thyroid or the tumor minimally invasive, e.g., infiltration of the strap muscle 
or infiltration of the perithyroid tissue; T4a, tumor of any size infiltrating the subcutaneous tissue, larynx, trachea, esophagus or recurrent 
laryngeal nerve; T4b, tumor of any size infiltrating prevertebral fascia, carotid artery, mediastinal vessels; N1a, metastases to cervical  
lymph nodes of the central system; N1b, metastases to lateral cervical lymph nodes; M1, distant metastases; N0 or M0, no corresponding 
metastases.
Table 2 The most commonly applied prognostic scales in papillary differentiated carcinomas 
AGES scale MACIS scale AMES scale 
Algorithm: PS =0.05× age in years  
(patients <40 years of age =0),  
+1 for G2 or +2 for G3 or G4,  
+1 if extracapsular invasion,  
+3 if distant metastases,  
+0.2× tumor size (diameter of cancer in cm)
Algorithm: PS =3.1× (age <39 years)  
or 0.08× (age >40 years),  
+0.3× tumor size in cm,  
+1 if partial thyroidectomy was done, 
+1 if cancer is locally advanced,  
+3 if distant metastases 
Assessment of age and sex,  
the presence of distant metastases,  
local advancement, extrathyroidal extension,  
size tumor in cm 
Risk groups depending on the  
calculated risk rate of PS:  
I, 0–3.99; II, 4–4.99;  
III, 5–5.99; IV >6
Risk groups depending on the 
calculated risk rate of PS:  
I, 0–5.99; II, 6–6.99;  
III, 7–7.99; IV >8
Risk group I—low risk:  
men <41 years of age, women <51,  
no distant metastases, cancer limited to the thyroid, 
tumor diameter <5 cm; risk group II—high risk: men 
>40 years of age, women >50, distant metastases, 
extracapsular extension, tumor diameter >5 cm
PS, prognostic score.
catalytic center of the protein (BRAF V600E mutation). 
Finding this mutation is possible not only in postoperative 
material but also, which is more significant, in fine needle 
aspiration biopsy material and may be known at diagnosis of 
PTC (17,18).
The relationship of BRAF mutation with other 
clinico-pathological risk factors 
The first reports on the significance of BRAF mutation 
in the pathogenesis of PTC (19-23) were noted in 2003. 
Further studies focused on searching the relationship 
between the mutation and other features of an unfavorable 
course of the disease (22-31). As early as in 2003 Nikiforova 
et al. (23) paid attention to the relationship between BRAF 
mutation and advanced age of patients and also histological 
subtypes of cancer (classic and tall cell PTC, extracapsular 
extension and a frequent incidence in patients in III and 
IV stages. The authors also indicated a more prevalent 
presence of the mutation in low-differentiated and 
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anaplastic cancers, which suggested the possibility for the 
mutation to be related to undifferentiation of PTC, which 
may result in a less favorable prognosis. Other observations 
were noted in the following years. A number of studies from 
single centers were reported, which analyzed the prevalence 
of the mutation and its relationship with other clinico-
pathological risk factors (24-33). However, the studies 
resulted in different, often conflicting results, which were 
related to differences in methodology, i.e., group selection, 
group size, time of the follow-up and the type of statistical 
analyses (uni- and/or multi-variable), the differences in 
BRAF mutation occurrence in different populations, the 
methodology of BRAF identification and also lack of the 
results of validations. Interestingly, initially none of the 
studies demonstrated the relationship of the mutation with 
the presence of distant metastases, i.e., the relationship with 
the strongest factor of an unfavorable prognosis in PTC, 
most probably due to rare occurrence of metastases (24-33) 
(Table 3). 
Only in a few studies a relationship between the presence 
of the mutation and the decrease in disease-free survival was 
observed (26,28,34). Elisei et al. in 2008 demonstrated the 
relationship between the presence of BRAF mutation and a 
decrease in overall and disease-free survival in a group of 102 
patients with the mean follow-up of 10 years or longer (28). 
That study strongly indicated BRAF mutation as an 
independent, unfavorable prognostic factor in PTC. 
Due to a silent biology of PTC and the generally 
favorable clinical course of this cancer, it is necessary to 
analyze groups large in size with a long follow-up to observe 
any significant differences between them. Consequently, 
no objective prospective, randomized clinical trials were 
conducted in the past, which could have been the basis for 
an evidence-based medicine. 
Meta-analyses assessing the prognostic 
significance of BRAF mutation 
Four meta-analyses were conducted due to the lack of 
possibility to run prospective studies for the objective 
assessment of prognostic significance of BRAF mutation.
In 2007 Lee et al. (35) analyzed 12 papers confirming 
the relationship between BRAF mutation and the extent 
of clinical advancement, extrathyroid extension and a 
histological sub-type. Five years later Li et al. analyzed 32 
studies and additionally demonstrated the coexistence of the 
mutation with the presence of lymph node (LN) metastases, 
more advanced age and the male sex (36). However, in 
these papers the relationship between the mutation and 
the prognosis was not analyzed. Such a study was done 
by Kim et al. (37). Based on 27 papers these authors also 
confirmed the relationship between the mutation and 
extrathyroid extension, LN metastases and the diagnosis of 
more advanced cancer (according to the TNM). However, 
in eight papers the relationship between the mutation 
and a higher risk of persistent disease or recurrence was 
also confirmed [patients with the mutation had 2.14-fold 
increased risk of recurrent and persistent disease (95% CI, 
1.67–2.74)].
Another meta-analysis by Tufano et al. assessed the 
Table 3 Correlation of BRAF mutation with selected clinico-pathological prognostic factors in selected publications (24-33)
Author Type of analysis
Number of 
BRAF (+) [%]
Age Sex
Extrathyroidal, 
extension
Lymph node 
metastases
Distant 
metastases
Rosenbaum et al. (24) Univariate 54 [65] 0.0001 – – – –
Kim et al. (25) Univariate; multivariate 149 [73] NS 0.0060; 0.0400 0.0600; 0.0050 NS; 0.0200 –
Kebebew et al. (26) Univariate 133 [49] 0.0300 NS NS NS NS
Lupi et al. (27) Univariate; multivariate 217 [44] NS NS 0.0001; NS 0.0009; NS –
Elisei et al. (28) Univariate 38 [37] 0.0200 NS NS NS NS
Costa et al. (29) Univariate 27 [55] NS – NS – NS
Wang et al. (30) Univariate; multivariate 54 [50] 0.0200 NS 0.0200; 0.0050 – –
Frasca et al. (31) Univariate; multivariate 125 [39] – – 0.0001; 0.0003 0.0001; 0.0070 –
Ito et al. (32) Univariate; multivariate 242 [38] 0.0500 NS NS 0.0050; 0.0001 NS
Guan et al. (33) Univariate 639 [62] NS NS 0.0030 0.0050 NS
NS, non-statistical significance; –, non-analyzed.
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correlation between BRAF mutation and recurrence or 
persistent disease (38). It analyzed 14 papers (the number 
of patients assessed from 9 countries was 2,470 in total). 
The authors considered only the reports which discussed 
the relationship between the recurrence rate and BRAF 
mutation and other classic clinico-pathological factors (e.g., 
LN metastases, extrathyroid extension, and more advanced 
disease; III and IV stages; AJCC). That study confirmed 
a significantly higher risk of relapse in a group of patients 
with confirmed BRAF mutation [BRAF (+)] as compared to 
a group of patients with BRAF wild type [BRAF (−)] (24.9% 
vs. 12.6%; P<0.00001). However, in the papers included 
in this analysis, the risk of relapse ranged significantly, i.e., 
for BRAF (+) patients from 11–40% (mean 26.5%) and for 
BRAF (−) patients from 2–36% (mean 9.5%).
The results of a multicenter retrospective study 
of the relationship of BRAF mutation with the 
prognosis
Xing designed and coordinated a large retrospective 
international multicentre study to eliminate limitations 
of meta-analyses for the assessment of the relationship of 
BRAF mutations with the prognosis in PTC. 
The analysis of the relationship of the mutation and the 
risk of death
The first stage included the assessment of the relationship 
of BRAF mutation with the risk of death in PTC patients. 
Xing et al. analyzed 1,849 patients treated in 13 centers in 
seven countries with the mean follow-up of 33 months (39).
The mortality in these patients was 3% (56/1,849). The 
mortality rate was significantly lower in patients with BRAF 
mutation (P<0.001), 45 deaths (5.3%) were reported in a 
group of BRAF (+) patients and only 11 (1.1%) in a group of 
BRAF (−) patients. The overall survival was lower in patients 
in whom the mutation was present. The additional analysis 
of the overall survival depending on the presence of the 
mutation and LN metastases demonstrated that BRAF (+) 
patients with LN metastases constituted the group with the 
most unfavorable prognosis. The assessment of interactions 
between BRAF mutation and other risk factors such as LN 
metastases, distant metastases, age of patients, extrathyroid 
extension and IV stage of clinical involvement demonstrated 
a strong relationship between the mutation and each of the 
above factors except for extrathyroid extension. However, 
in the multivariate analysis after adding the features of 
unfavorable disease course such as age, sex, extrathyroid 
extension, LN metastases or distant metastases, the 
relationship between BRAF and mortality lost a statistical 
significance, probably due to a low incidence of deaths.
The analysis of the relationship of the mutation with the 
risk of recurrence
The next stage was based on the assessment of the 
relationship between BRAF mutation and the risk of 
recurrence. Two thousand ninety nine patients from 16 
centers and eight countries with the mean follow-up of 
36 months were enrolled in the analysis (40). Recurrence 
was defined altogether as local recurrence, distance 
recurrence and persistent disease. BRAF mutation was done 
on postoperative material therefore its status did not have an 
influence on the treatment applied. Disease recurrence was 
noted in 16.1% of patients. Recurrence was more frequent 
in patients with the mutation (20.9%) as compared to 
BRAF (−) patients (11.6%) (P=0.000). A higher risk of 
relapse was typical of BRAF (+) patients. The relationship 
was observed also in the multivariable analysis which 
considered age, sex, the center from which patients came 
from, tumor size, extrathyroid extension, LN metastases, 
multifocality and a histological subtype of the cancer. 
Disease-free survival was significantly lower in patients with 
PTC in whom the mutation was diagnosed (log-rank, 28.1; 
P<0.01). This relationship was also observed in the classic 
subtype and in follicular subtype of PTC. Additionally, 
the worst disease-free survival was noted in BRAF (+) 
patients in whom LN metastases were diagnosed (log-rank, 
143.6; P<0.001). A similar observation was related to the 
coexistence of the mutation with extracapsular infiltration 
and with the age of patients (>60 years of age) (log-rank, 
68.9; P<0.001). 
The relationship of BRAF mutation with a higher 
risk of relapse was also confirmed in low-risk patients (I 
and II AJCC stages and in microcarcinoma). The study 
demonstrated that BRAF mutation was an independent 
unfavorable prognostic factor related to a higher risk of 
recurrence. 
Critical remarks concerning a multicentre retrospective 
analysis of the relationship between the mutation and 
disease recurrence
These observations, however, did not dispel the controversy 
concerning prognostic and predictive significance of BRAF 
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mutation in PTC. After publishing the results of the 
analysis, the discussion in Journal of Clinical Oncology on 
the real relationship between the mutation and the cancer 
relapse was initiated. Bal et al. (41) argued that inaccurate 
definition of recurrence was used and the definition was 
applied also for persistent disease. The accusations were 
also related to a short median follow-up (36 months) and a 
relatively high incidence of recurrence. These accusations 
are not fully legitimate (42). In PTC persistent disease is 
commonly linked with the real recurrence due to the fact 
that routine follow-ups occur every 6 or 12 months and it is 
not possible to fully differentiate recurrence from persistent 
disease as defined in the classic oncological definition. 
Recurrence is the symptom occurrence after complete 
remission lasting up to 6 months after the end of treatment.
The majority of relapses occur in the first years of the 
follow-up, therefore a 3-year follow-up may be considered 
sufficient, and the reported percentage of recurrence (16%) 
is within the range given by other authors (9,42). 
Furthermore, Yarchoan et al. appreciated the value of the 
studies of Xing et al. as the largest multicenter retrospective 
study on prognostic significance of BRAF mutation (43).
These authors argue that current knowledge does not 
offer enough evidence on the application of BRAF status 
to the clinical practice. The authors stressed that it may 
unnecessarily result in anxiety among patients since the 
significance of BRAF for an unfavorable prognosis is still 
not strong enough. However, Yarchoan et al. argues that 
patients from low-risk groups may gain some benefit 
due to the knowledge on BRAF status (43). It is probable 
that patients classified into a low-risk group based on 
the classic prognostic factors and BRAF (−) could be 
treated conservatively, which is consistent with a current 
international trend. 
Disease recurrence and LN metastases
LN metastases are the most common cause of disease 
recurrence in PTC. The possibility of a preoperative 
assessment of the risk of LN metastases would be 
significant for a surgeon. As a result, patients might be 
properly qualified for central lymphadenectomy to avoid 
this prophylactic procedure and an unnecessary increase in 
incidence risk of postoperative complications (44,45). 
The attempt was made to use BRAF mutation in 
predicting the risk of metastases to cervical LNs (46). Based 
on uni- and multivariable analyses Joo et al. confirmed the 
relationship between the mutation and a higher risk of 
metastases to the central LNs, suggesting that prophylactic 
central neck dissection should be based on the assessment of 
BRAF mutation diagnosed in the fine needle aspiration (5). 
Howell et al. presented similar conclusions and their study 
confirmed the relationship between BRAF mutation and a 
risk of metastases to the central LNs (47). These authors 
expressed the opinion according to which preoperative 
assessment of BRAF mutation may be used to plan the 
extent of surgical treatment. 
Xing et al. in the multicenter study also confirmed 
a correlation between the mutation and the risk of LN 
metastases and a higher risk of recurrence (40). However, 
some studies did not confirm the presence of such a 
relationship (7,48,49).
The observed divergence is obviously related to a 
retrospective nature of the analyses, different group selection 
(different group size) and different time of follow-up. 
It is obvious that well designed prospective study could 
solve the existing controversies. 
Sadly, performing such a study does not seem to be 
real. Carling et al. assessed that it would be necessary to 
enroll almost 6,000 patients in the prospective analysis in 
order to demonstrate the benefit of prophylactic central 
lymphadenectomy (50). 
A critical approach to the practical application 
of the analysis of BRAF mutation as an 
independent molecular prognostic and predictive 
factor
The strongest argument against using BRAF mutation 
analysis as an independent prognostic and predictive risk 
factor in patients with PTC is its high prevalence (30–80%) 
whereas the risk of persistent disease or recurrence is related 
to about 30% of population (depending on the adopted 
definition of recurrence). 
At present, it seems that BRAF mutation is one of the 
factors influencing the prognosis and it should be analyzed 
in correlation with other prognostic factors (51). 
The most recent revision of ATA recommendations 
[2015] is also related to it. 
Despite the fact that previously Prescott et al. demonstrated 
that adding BRAF status to different commonly applied risk 
scales (AGES, AMES, MACIS, TNM and 2009 ATA initial 
risk stratification system) improves the possibility of the proper 
patient classification (52). It allows for a better prediction 
related to the risk of relapse. The 5-year cumulative recurrence 
incidence observed by these authors was 20% in BRAF (+) vs. 
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8% in BRAF (−) patients. BRAF was associated with the time 
to recurrence when it was added to the following risk-scales: 
AMES—HR 2.43, MACIS—HR 2.46, TNM—HR 2.51, ATA 
recurrence risk category—HR 2.44. 
Due to a lack of evident confirmation of a direct influence 
of mutation on the increase in relapse risk, ATA most recent 
recommendations do not indicate a routine application of 
BRAF status for initial risk stratification in differentiated 
thyroid cancer. However, due to the fact that a clinician 
may possess such knowledge, ATA demonstrates the 
continuous risk scale for the assessment of the risk of relapse, 
considering BRAF and/or TERT status (Figure 1) (53). 
Future perspectives and research directions
Currently, researchers are working on determining the role 
of BRAF mutation in the relapse risk assessment in patients 
from a low-risk group as indicated by the ATA scale.
Elisei et al. (54) initiated such studies and observed only 
3% of structural relapse in patients with thyroid limited 
carcinoma (T1–T2N0M0). However, in the case of BRAF (+) 
carcinoma, the recurrence rate was 8% as compared to the 
population of BRAF (−) 1% (P=0.0003). In the multivariable 
analysis only BRAF mutation was a predictive factor of 
persistent disease in a 5-year follow-up. If these observations 
were confirmed by other studies, the analysis of BRAF 
mutation for patients with carcinoma limited to the thyroid 
could result in better selection of low and intermediate risk 
groups, as suggested by Yarchoan et al. (43).
Recent reports suggest that tumors in which BRAF 
mutation coexists with other mutations such as TERT, 
PIK3CA and/or TP53 may be characterized by more 
2015 ATA Modified Initial Risk Stratification System
The tree-tiered risk system The continuum risk system
High risk:
Gross extrathyroidal extension 
Incomplete tumor resection, distant metastases,
or lymph node >3 cm
Intermediate risk:
Aggressive histology, minor extrathyroidal
extension, vascular invasion,
or >5 involved lymph nodes (0.2–3 cm)
Low risk:
Intrathyroidal DTC
5≤ lymph node micrometastases (<0.2 cm)
The highest risk ↓
FTC, extensive vascular invasion (~30–50%)
pT4a gross ETE (~30–40%)
pN1 with extranodal ext. >3 LN involved (~40%)
PTC >1 cm, TERT mut. ± BRAF mut. (>40%)
pN1, any LN >3 cm (~30%)
PTC, extrathyroidal, BRAF mut. (~10–40%)
PTC, vascular invasion (~15–30%)
Clinical N1 (~20%)
pN1, >5 LN involved (~20%)
Intrathyroidal PTC, <4 cm, BRAF mut. (~10%)
pT3 minor ETE (~3–8%)
pN1, ≤5 LN involved (~5%)
pN1, all LN <0.2 cm (~5%)
Intrathyroidal PTC 2–4 cm (~5%)
Multifocal PTMC (~4–6%)
pN1 without extranodal extension, ≤3 LN involved (2%)
Minimally invasive FTC (~2–3%)
Intrathyroidal, <4 cm, BRAF wt. (~1–2%)
Intrathyroidal unifocal PTMC, BRAF mut. (~1–2%)
Intrathyroidal, encapsulated, FV-PTC (~1–2%)
Unifocal PTMC (~1–2%)
The lowest risk ↑
Figure 1 The risk of structural disease recurrence in patients without structurally identifiable disease after initial therapy (according to 
ATA 2015). The risk of structural disease recurrence associated with selected clinico-pathological features are shown as a continuum of 
risk with percentage (ranges, approximate values). In the left column, the three-tiered risk system proposed as the modified initial risk 
stratification system is shown. While analysis of BRAF and/or TERT status is not routinely recommended for initial risk stratification 2015 
ATA recommendations included these findings to assist clinicians in proper risk stratification in cases where this information is available (53). 
FTC, follicular thyroid carcinoma; PTC, papillary thyroid cancer; FV, follicular variant; PTMC, papillary thyroid microcarcinoma; LN, 
lymph node; ETE, extrathyroidal extension; mut., mutated; wt., wild type.
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aggressive clinical course. It is believed that more accurate 
tumor prognostication is possible due to a genetic analysis 
(55-58).
Studies on the formation of sensitive and specific 
molecular classifiers are being conducted. Such classifiers 
might help in better assessment of the risk of relapse. 
Additionally, they might be valuable in the assessment of 
an unfavorable course of the disease and might be useful in 
personalized therapeutic strategy. Currently, it seems that 
the analysis of molecular factors will be one of the major 
research trends in the following years (59-62).
Summary
The opinion of Puxeddu according to which we cannot 
use the analysis of BRAF mutation as a single, independent 
predictive factor in clinical practice seems to be the correct 
approach (63). However, its usefulness in the context 
of other molecular and clinico-pathological risk factors 
cannot be excluded. In the future they may be used to 
make modern prognostic scales of relapse risk and, as a 
result, may be applied to plan individual optimal diagnostic 
and therapeutic strategy for patients with PTC, which is 
consistent with the most recent ATA recommendations. 
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